Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Milacemide"'
Publikováno v:
Brain Research Bulletin. 168:165-177
The discovery and development of safinamide, an alpha-aminoamide, has been a valuable addition to the existing clinical management of Parkinson’s disease (PD). The journey of safinamide dates back to the year 1983, when an alpha-aminoamide called m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d83d8143ab139d06a793245cb4869509
https://doi.org/10.1016/j.brainresbull.2020.12.018
https://doi.org/10.1016/j.brainresbull.2020.12.018
Autor:
J. Tonkiss, J. N. P. Rawlins
Rats were trained to alternate responses on a discrete trial working memory task on a T-maze. In Experiment 1, the rats were then matched for choice accuracy and allocated to three treatment groups. These were: implantation of osmotic minipumps for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6725f91e94c4fff3e76fdde8b1655d7c
https://ora.ox.ac.uk/objects/uuid:b770086d-1fc0-4f36-8436-06cf69cbe607
https://ora.ox.ac.uk/objects/uuid:b770086d-1fc0-4f36-8436-06cf69cbe607
Publikováno v:
Biochemical Pharmacology. 50:317-324
Oxidation of the anticonvulsant drug milacemide [2- n -(pentylamino)acetamide] by monoamine oxidase-B (MAO-B) has been reported to be important in terminating its activity. Comparison of the oxidation of this compound by MAO-B preparations from ox an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c766a29dd9c4c542a7b35317ab22601
https://doi.org/10.1016/0006-2952(95)00145-p
https://doi.org/10.1016/0006-2952(95)00145-p
Publikováno v:
Neurochemical Research. 19:161-165
Twenty four hours after mice were forced to swim for up to 10 minutes in cold water, there was a reduction in the ability of MK-801 to antagonize the electrical precipitation of tonic hindlimb extension. Milacemide, a lipophilic prodrug of glycine, r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95583870dfc437114b5b6e63ba86c138
https://doi.org/10.1007/bf00966811
https://doi.org/10.1007/bf00966811
Publikováno v:
Journal of the American Chemical Society. 115:4949-4954
The anticonvulsant agent milacemide (2-(n-pentylamino)acetamide) is known to inactivate monoamine oxidase-B (MAO-B). Various isotopically labeled analogues of milacemide are used to elucidate the mechanism of inactivation of MAO-B by this compound. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::760437f19b742d13dba0a86c1af4730e
https://doi.org/10.1021/ja00065a001
https://doi.org/10.1021/ja00065a001
Publikováno v:
British Journal of Pharmacology. 108:1117-1124
1. The kinetics and metabolism of milacemide have been studied in an animal model which allows the simultaneous investigation of the temporal inter-relationships of drugs and metabolites in blood (pharmacokinetics) and cerebrospinal fluid (CSF, neuro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1c6387bf876797447e02156db496a6e
https://doi.org/10.1111/j.1476-5381.1993.tb13514.x
https://doi.org/10.1111/j.1476-5381.1993.tb13514.x
Autor:
Fumisuke Matsuo, Hugh C. Hendrie, Robert L. Herting, John J. Sramek, Neal R. Cutler, Ward T. Smith, T. Daniel Fakouhi
Publikováno v:
Journal of Geriatric Psychiatry and Neurology. 6:115-119
A multicenter, double-blind, placebo-controlled, parallel group study was conducted to assess the safety and efficacy of three doses of milacemide in the treatment of patients with senile dementia of the Alzheimer type of mild to moderate severity. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2d27448e4ebd4e28046a0afbc8ec389
https://doi.org/10.1177/089198879300600210
https://doi.org/10.1177/089198879300600210
Autor:
Jun'ichi Semba, Philip N. Patsalos
Publikováno v:
European Journal of Pharmacology. 230:321-326
The temporal inter-relationship of various amino acids and monoamine metabolites in rat cerebrospinal fluid was examined after acute administration of milacemide (100, 200 or 400 mg/kg i.p.), a glycine prodrug. Glycine concentrations rose linearly an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72fe45d17dfdf9c94cb5a15d4fb5e44b
https://doi.org/10.1016/0014-2999(93)90568-3
https://doi.org/10.1016/0014-2999(93)90568-3
Publikováno v:
Movement Disorders. 8:47-50
The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double-blind, placebo-controlled conditions. When administered as monotherapy at a single oral dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ad1cd6f7277de99731bf8ea4b1d105
https://doi.org/10.1002/mds.870080109
https://doi.org/10.1002/mds.870080109
Autor:
Claude Delatour, Jean-Pierre Van Hoeck, Anne M. Mockel, Hugo Gorissen, Guido H. Journée, Valéry R. Libert
Publikováno v:
Chirality. 4:286-294
Both (R)- and (S)-4-hydroxypentylaminoacetamide have been synthesized by reductive amination of glycinamide on the γ-valerolactols corresponding to (R)- and (S)-γ-valerolactone, respectively. These enantiomeric lactones were readily obtained in hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee154e4a6af8634cb56efbac7546b373
https://doi.org/10.1002/chir.530040505
https://doi.org/10.1002/chir.530040505